MX2023011608A - Metodos para inhibir ras. - Google Patents
Metodos para inhibir ras.Info
- Publication number
- MX2023011608A MX2023011608A MX2023011608A MX2023011608A MX2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inhibit ras
- ras
- inhibit
- ras proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170292P | 2021-04-02 | 2021-04-02 | |
| US202163192843P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/023133 WO2022212894A1 (en) | 2021-04-02 | 2022-04-01 | Methods for inhibiting ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011608A true MX2023011608A (es) | 2023-12-14 |
Family
ID=83456876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011608A MX2023011608A (es) | 2021-04-02 | 2022-04-01 | Metodos para inhibir ras. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240108630A1 (https=) |
| EP (1) | EP4320143A4 (https=) |
| JP (1) | JP2024512767A (https=) |
| KR (1) | KR20240004436A (https=) |
| AU (1) | AU2022249177A1 (https=) |
| BR (1) | BR112023020182A2 (https=) |
| CA (1) | CA3214155A1 (https=) |
| CR (1) | CR20230500A (https=) |
| IL (1) | IL307396A (https=) |
| MX (1) | MX2023011608A (https=) |
| TW (1) | TW202308632A (https=) |
| WO (1) | WO2022212894A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023199180A1 (en) * | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| CN119301132A (zh) * | 2022-06-01 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的卤代吲哚大环化合物 |
| CN117720556A (zh) * | 2022-09-19 | 2024-03-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物及其制备方法和用途 |
| EP4582426A4 (en) * | 2022-09-19 | 2025-12-24 | Adlai Nortye Biopharma Co Ltd | PAN-KRAS INHIBITOR COMPOUND |
| CN119522225A (zh) | 2022-09-29 | 2025-02-25 | 广州嘉越医药科技有限公司 | 大环衍生物及其应用 |
| WO2024104364A1 (zh) * | 2022-11-16 | 2024-05-23 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| CN117534684A (zh) * | 2022-11-29 | 2024-02-09 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
| IL322278A (en) * | 2023-02-06 | 2025-09-01 | Bicara Therapeutics Inc | Combined therapy and related methods |
| CR20250329A (es) | 2023-02-14 | 2025-09-12 | Hoffmann La Roche | Compuestos tricíclicos para el tratamiento del cáncer |
| WO2024187174A2 (en) * | 2023-03-09 | 2024-09-12 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| EP4687905A1 (en) * | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025051241A1 (zh) * | 2023-09-06 | 2025-03-13 | 劲方医药科技(上海)股份有限公司 | 大环化合物及其抗体-药物偶联物 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025087431A1 (zh) * | 2023-10-27 | 2025-05-01 | 贝达药业股份有限公司 | 泛-kras抑制剂及其在医药上的应用 |
| WO2025093625A1 (en) * | 2023-11-01 | 2025-05-08 | F. Hoffmann-La Roche Ag | Macrocycle compounds for the treatment of cancer |
| WO2025119392A1 (zh) * | 2023-12-08 | 2025-06-12 | 正大天晴药业集团股份有限公司 | 含有酰胺取代的大环类化合物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025193628A2 (en) * | 2024-03-09 | 2025-09-18 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025252241A1 (zh) * | 2024-06-07 | 2025-12-11 | 杭州和正医药有限公司 | 一种大环衍生物及其用途 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015745A1 (en) * | 2024-07-11 | 2026-01-15 | Treeline Biosciences, Inc. | Macrocyclic ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR20210116479A (ko) * | 2018-12-21 | 2021-09-27 | 레볼루션 메디슨즈, 인크. | 공동 결합에 참여하는 화합물 및 그의 용도 |
| MX2023003060A (es) * | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
-
2022
- 2022-04-01 IL IL307396A patent/IL307396A/en unknown
- 2022-04-01 EP EP22782324.2A patent/EP4320143A4/en active Pending
- 2022-04-01 WO PCT/US2022/023133 patent/WO2022212894A1/en not_active Ceased
- 2022-04-01 CA CA3214155A patent/CA3214155A1/en active Pending
- 2022-04-01 MX MX2023011608A patent/MX2023011608A/es unknown
- 2022-04-01 AU AU2022249177A patent/AU2022249177A1/en active Pending
- 2022-04-01 JP JP2023560831A patent/JP2024512767A/ja active Pending
- 2022-04-01 TW TW111112802A patent/TW202308632A/zh unknown
- 2022-04-01 KR KR1020237037749A patent/KR20240004436A/ko active Pending
- 2022-04-01 BR BR112023020182A patent/BR112023020182A2/pt unknown
- 2022-04-01 CR CR20230500A patent/CR20230500A/es unknown
-
2023
- 2023-10-02 US US18/479,500 patent/US20240108630A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202308632A (zh) | 2023-03-01 |
| AU2022249177A1 (en) | 2023-10-19 |
| EP4320143A1 (en) | 2024-02-14 |
| IL307396A (en) | 2023-12-01 |
| KR20240004436A (ko) | 2024-01-11 |
| BR112023020182A2 (pt) | 2023-12-12 |
| WO2022212894A1 (en) | 2022-10-06 |
| CR20230500A (es) | 2024-02-13 |
| US20240108630A1 (en) | 2024-04-04 |
| CA3214155A1 (en) | 2022-10-06 |
| EP4320143A4 (en) | 2025-02-19 |
| JP2024512767A (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011608A (es) | Metodos para inhibir ras. | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| CO2020002588A2 (es) | Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
| BR112018074395A2 (pt) | derivados de pirazol como inibidores de calicreína plasmática | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| BR112018074621A2 (pt) | derivados de pirazolopirimidina como inibidores de quinase | |
| MX2023001193A (es) | Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2. | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| BR112022010633A2 (pt) | Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção | |
| MX2018008939A (es) | Anticuerpos anti-factor de la coagulacion xi. | |
| CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| BR112018068341A2 (pt) | 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj | |
| MX2020009154A (es) | Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer. | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| GEAP202215303A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| MX388890B (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| CL2019002854A1 (es) | Compuesto macrocíclico y sus usos. | |
| CL2020003306A1 (es) | Composiciones bifuncionales para el tratamiento del cáncer. | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| BR112018014247A2 (pt) | inibição de reação alérgica usando um inibidor il-33 | |
| MX388815B (es) | Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia. |